{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:44Z","timestamp":1790855564745,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M693516"],"award-info":[{"award-number":["2021M693516"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82161138005"],"award-info":[{"award-number":["82161138005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22107117"],"award-info":[{"award-number":["22107117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22001267"],"award-info":[{"award-number":["22001267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115217","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:24:40Z","timestamp":1676895880000},"page":"115217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors"],"prefix":"10.1016","volume":"250","author":[{"given":"Ke","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115217_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00005-017-0491-5","article-title":"Immunotherapy as an option for cancer treatment","volume":"66","author":"Rusch","year":"2018","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.ejmech.2023.115217_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115217_bib3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/vaccines9060614","article-title":"The evolution of cancer immunotherapy","volume":"9","author":"Khan","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ejmech.2023.115217_bib4","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1073\/pnas.0508996103","article-title":"Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase","volume":"103","author":"Sugimoto","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115217_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115217_bib6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejmech.2023.115217_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-3-319-67577-0_9","article-title":"Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression","volume":"1036","author":"Amobi","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2023.115217_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2023.115217_bib9","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115217_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues","volume":"3","author":"Theate","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejmech.2023.115217_bib11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115217_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.lungcan.2009.05.001","article-title":"Increased serum kynurenine\/tryptophan ratio correlates with disease progression in lung cancer","volume":"67","author":"Suzuki","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2023.115217_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2023.115217_bib14","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115217_bib15","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","article-title":"Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"58","author":"R\u00f6hrig","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib16","doi-asserted-by":"crossref","first-page":"15115","DOI":"10.1021\/acs.jmedchem.0c00925","article-title":"Development of indoleamine 2,3-dioxygenase 1 inhibitors for cancer therapy and beyond: a recent perspective","volume":"63","author":"Feng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11912-019-0750-1","article-title":"Indoleamine dioxygenase inhibitors: clinical rationale and current development","volume":"21","author":"Zhu","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2023.115217_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115217_bib19","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1021\/acs.jmedchem.9b00662","article-title":"Discovery of clinical candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1","volume":"62","author":"Kumar","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib20","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115217_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1021\/acsmedchemlett.0c00668","article-title":"Discovery and preclinical evaluation of BMS-986242, a potent, selective inhibitor of indoleamine-2,3-dioxygenase 1","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115217_bib22","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","article-title":"Discovery of a Novel and Selective Indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and its characterization as a potential clinical candidate","volume":"60","author":"Crosignani","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CJI.0000000000000368","article-title":"A phase I study of an IDO-1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer","volume":"44","author":"Kotecki","year":"2021","journal-title":"J. Immunother."},{"key":"10.1016\/j.ejmech.2023.115217_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115217_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejmech.2023.115217_bib26","doi-asserted-by":"crossref","first-page":"17950","DOI":"10.1021\/acs.jmedchem.1c01305","article-title":"Discovery of the first potent IDO1\/IDO2 dual inhibitors: a promising strategy for cancer immunotherapy","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1021\/acs.jmedchem.2c01954","article-title":"Dual nicotinamide phosphoribosyltransferase (NAMPT) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors for the treatment of drug-resistant nonsmall-cell lung cancer","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/acsmedchemlett.7b00487","article-title":"Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) dual inhibitors","volume":"9","author":"Fang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115217_bib29","doi-asserted-by":"crossref","first-page":"15642","DOI":"10.1021\/acs.jmedchem.2c00771","article-title":"Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma","volume":"65","author":"Bollu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib30","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115217_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112059","article-title":"Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors","volume":"189","author":"Song","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41467-017-01725-8","article-title":"Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1","volume":"8","author":"Lewis-Ballester","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115217_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111629","article-title":"Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer","volume":"182","author":"Du","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejmech.2019.06.037","article-title":"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors","volume":"179","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/acsmedchemlett.9b00572","article-title":"Discovery of hydroxyamidine based inhibitors of IDO1 for cancer immunotherapy with reduced potential for glucuronidation","volume":"11","author":"Steeneck","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115217_bib36","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1021\/acs.jmedchem.9b01541","article-title":"Urea derivatives in modern drug discovery and medicinal chemistry","volume":"63","author":"Ghosh","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib37","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","article-title":"Challenges in the Discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"58","author":"R\u00f6hrig","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115217_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115217_bib39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JAD-2010-100684","article-title":"Oren-gedoku-to and its constituents with therapeutic potential in alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro","volume":"22","author":"Yu","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2023.115217_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111750","article-title":"Effective virtual screening trategy toward heme-containing proteins: identification of novel IDO1 inhibitors","volume":"184","author":"Zou","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:52:10Z","timestamp":1778676730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":40,"alternative-id":["S0223523423001836"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115217","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115217"}}